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Abstract
Ajulemic acid (AJA, CT-3, IP-751, JBT-101, anabasum) is a first-in-class, syn-
thetic, orally active, cannabinoid-derived drug that preferentially binds to the
CB2 receptor and is nonpsychoactive. In preclinical studies, and in Phase 1 and
2 clinical trials, AJA showed a favorable safety, tolerability, and pharmacokinetic
profile. It also demonstrated significant efficacy in preclinical models of inflam-
mation and fibrosis. It suppresses tissue scarring and stimulates endogenous
eicosanoids that resolve chronic inflammation and fibrosis without causing
immunosuppression. AJA is currently being developed for use in 4 separate but
related indications including systemic sclerosis (SSc), cystic fibrosis, dermato-
myositis (DM), and systemic lupus erythematosus. Phase 2 clinical trials in the
first 3 targets demonstrated that it is safe, is a potential treatment for these
orphan diseases and appears to be a potent inflammation-resolving drug with a
unique mechanism of action, distinct from the nonsteroidal anti-inflammatory
drug (NSAID), and will be useful for treating a wide range of chronic inflamma-
tory diseases. It may be considered to be a disease-modifying drug unlike most
NSAIDs that only provide symptomatic relief. AJA is currently being evaluated
in 24-month open-label extension studies in SSc and in skin-predominant DM.
A Phase 3 multicenter trial to demonstrate safety and efficacy in SSc has
recently been initiated.
K E YWORD S
CB2, inflammation-resolving, disease-modifying, antimetastatic, systemic sclerosis
1 | INTRODUCTION
The chemical structure of ajulemic acid (AJA) is shown in Figure 1.
It is a synthetic analog of THC-11-oic acid, the principle metabolite
of tetrahydrocannabinol (THC), the mood-altering component of
Cannabis. AJA, unlike THC, does not produce behavioral changes
either in animals or in humans; however, it does retain several of
the therapeutically useful actions of THC. A recent review
describes in a concise manner the nature of these activities.1 This
review will focus on the remarkable progress that has been
reported since the previous review, mainly in the clinical develop-
ment of AJA as an inflammation-resolving agent. In addition,
Abbreviations: AJA, ajulemic acid; AUC, area under the curve; BAL, bronchoalveolar lavage; BLM, bleomycin; BrdU, 5-bromo-2-deoxyuridine; CF, cystic fibrosis; CFTR, cystic fibrosis
transmembrane conductance regulator; CFUs, colony forming units; CNS, central nervous system; CRISS, Combined Response Index in Diffuse Cutaneous Systemic Sclerosis; CYP1A2,
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several of its potentially important preclinical actions are now
reviewed in some detail.
2 | BACKGROUND AND HISTORY
The preclinical literature on AJA has been briefly reviewed,2 how-
ever, in this presentation, several selected, as well as newly reported
areas, are discussed in more detail. These have been chosen because
they suggest therapeutic targets where AJA may be efficacious in
the treatment of human disease. Specifically, they are arthritis, fibro-
sis and metastatic disease. Each of the 3 represent a major under
met medical need.
2.1 | Rheumatoid arthritis
Joint tissue injury in patients with rheumatoid arthritis (RA) is
due in part to activation of T lymphocytes in the synovia; T lym-
phocytes in synovia of RA patients are resistant to apoptosis.
Oral administration of AJA prevents joint cartilage and bone
damage in an experimental model of arthritis in rats.3 Thus, a
potential mechanism whereby AJA prevents joint tissue injury in
this animal model might be an enhanced apoptosis of T lympho-
cytes. Apoptosis of human T cells in vitro was assessed by
annexin V expression, caspase-3 activity, DNA fragmentation, and
microscopy.4,5 AJA induced apoptosis of T cells in a dose- and
time-dependent manner. Apoptosis preceded loss of cell viability
by trypan blue dye exclusion, confirming that cell loss was due
to programmed death rather than necrosis. This suggests that a
nontoxic compound such as AJA may be a useful therapeutic
agent for patients with diseases such as RA that are character-
ized by T-cell-driven chronic inflammation and tissue injury.
Reduced T-cell proliferation was promoted by the addition of
AJA to cells 60 minutes before stimulation with anti-CD3/CD4
monoclonal antibodies. AJA suppressed 5-bromo-2-deoxyuridine
(BrdU) incorporation in a concentration-dependent manner; half-
maximal inhibition was achieved with concentrations lower than
1 lmol/L.
Because activation of osteoclasts is essential in the pathogenesis
of bone erosion in patients with RA, the influence of AJA on osteo-
clast differentiation and survival was studied. Osteoclast cultures
were established by stimulation of RAW264.7 (RAW) cells, and pri-
mary mouse bone marrow cultures, with the receptor activator of
NF-kappa B ligand (RANKL).5 Simultaneous addition of AJA (15 or
30 lmol/L) and RANKL to both culture systems significantly sup-
pressed development of multinucleated osteoclasts (osteoclastogene-
sis) in a dose-dependent manner, as determined by quantification of
multinuclear, tartrate-resistant, acid phosphatase-positive cells. AJA
impaired growth of RAW264.7 monocytes and prevented further
osteoclast formation in cultures in which osteoclastogenesis had
already begun. Reduction by AJA of both monocyte growth and
osteoclast formation was associated with apoptosis, assayed by
annexin V, propidium iodide staining, and caspase activity. The
antiosteoclastogenic effects of AJA did not require the continuous
presence of AJA in the cell cultures. Based on these findings, it
seems likely that AJA may be a useful drug for diseases such as RA
and osteoporosis in which bone resorption is a central feature.
2.2 | Multiple sclerosis
In multiple sclerosis (MS), damage to myelin in the central nervous sys-
tem (CNS) and to the nerve fibers themselves interferes with the
transmission of nerve signals between the brain, the spinal cord, and
other parts of the body. The loss of myelin promotes several inflamma-
tory processes, which results in the release of soluble factors like
cytokines and antibodies that further perpetuates nerve damage. Data
were obtained in a mouse model of experimental autoimmune
encephalomyelitis (EAE) at doses of 0.1 and 1.0 mg/kg AJA. It was
identified as a substance that is able to reduce MS-induced spasticity
presumably by its inflammation resolving action on peripheral nerves.6
2.3 | Antifibrotic effects
Bleomycin (BLM)-induced experimental fibrosis in mice was used to
assess the antifibrotic effects of AJA in vivo.7,8 Initially, acute inflam-
mation characterized by neutrophil and macrophage accumulation
were the main changes present in lung parenchyma.8 Between 8 and
14 days after BLM administration, the response progresses from
inflammation to fibrosis and involves the bronchi and vasculature.
The fibrotic response in lung tissue at day 21 after BLM treatment
was significantly reduced in mice receiving either AJA in the inflam-
matory or in the early fibrogenic phase. A marked change in the
expression pattern of substances implicated in fibrogenesis, such as
TGF-b1, pSMAD2/3, CTGF, and a-SMA was observed.
2.4 | Cancer and antimetastatic effects
Early observations on inhibition of cell proliferation by AJA (Burstein
SH and Zurier RB, unpublished) prompted a study of its possible
anticancer actions.9 AJA was compared with THC as an antineoplas-
tic agent and was found to be nearly equipotent in vitro and more
F IGURE 1 The structure of ajulemic acid. (6aR,10aR)-1-hydroxy-
6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]
chromene-9-carboxylic acid. Molecular formula: C25H36O4. Exact
mass: 400.261 g/mol. It is asynthetically modified analog of THC-11-
oic acid, the principal metabolite of THC. THC, tetrahydrocannabinol
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effective than THC in vivo. For example, at 14 days following inocu-
lation of glioma cells, tumor diameter was 50% less in AJA-treated
mice when compared to vehicle or THC-treated animals. Data
obtained with the CB2 receptor antagonist SR144528 suggested
that CB2 was involved in the mechanism of the antitumor action.
It has been proposed that inflammation can be promoted by
endogenous mediators through Toll-like receptors (TLRs) to enhance
tumor progression and metastasis.10 Many studies have shown a
correlation between TLR signaling and tumor progression and metas-
tasis; endogenous mediators, including HMGB1 (high mobility group
box 1), have been implicated in the triggering of tumor-associated
inflammation. A gene array study showed that AJA significantly
reduced the expression of TLR 3, 5, 7, 8, and 9 (Skulas A and Zurier
RB, personal communication) suggesting a role for these receptors in
the antimetastatic effects of AJA.
Inflammation in the tumor microenvironment that is mediated by
IL-1b is believed to have an important role in cancer invasiveness,
progression, and metastases.11 Thus, further support for the anti-
cancer action of AJA comes from the report that it can inhibit the
production of IL-1b.12 An example of such a mechanism comes from
a randomized, double-blind, placebo-controlled trial of the IL-1b inhi-
bitor, canakinumab.13 Thus, it is quite reasonable to suggest that IL-
1b inhibitors, such as AJA, could produce a similar therapeutic action
without side effects.
Based on the earlier encouraging findings, a study of the effect of
AJA on survival time was initiated (Recht L and Salmonsen R, personal
communication). SCID-NOD mice (n = 5/group) were inoculated sub-
cutaneously with glioma cells and the course of the cancer was fol-
lowed up for 28 days. The survival data are shown in Figure 2. These
limited data suggest a modest improvement in survival with the lower
dose being more effective. Of greater interest is the possible reduction
of metastatic disease in the AJA-treated mice as evidenced by the
absence of ascites and a better overall condition of the AJA-treated
mice. This may be partly due to the anti-inflammatory properties of
AJA and to its effect on several matrix metalloproteinases.14 Also, the
appearance of the primary tumors was different in the drug-treated
mice vs. the vehicle-treated mice. The AJA-treated mice had discrete
well-defined tumors, whereas the vehicle-treated control mice pro-
duced diffuse, poorly defined tumors; the latter is typical of the human
clinical situation and is a major problem in the treatment of glial cell
brain cancer. This suggests that AJA, with its good safety profile,
would be a useful follow up long-term treatment to suppress the
development of metastatic disease.
2.5 | A medical countermeasure against nerve and
blister agents
Inflammatory cytokines and proteolysis are implicated in the toxicity
of both the blister agent sulfur mustard (SM [2,20-dichlorodiethyl sul-
fide]) and the nerve agent soman.15 Synthetic analogs of THC can
have potent anti-inflammatory effects that involve inhibition of cyto-
kine activity without significant psychotropic action.2 The ability of
AJA to reduce the increased inflammatory cytokines IL-8 and TNF in
SM-exposed human epidermal keratinocyte cultures was evaluated
by the U.S. Army Medical Research Institute of Chemical Defense
(USAMRICD (Atlantic Pharmaceuticals, unpublished)). AJA dose
dependently suppressed IL-8 and TNF in HD-exposed human epider-
mal keratinocyte cultures; AJA was added 1 hour following SM
treatment. SM-induced increases in both cytokines were completely
inhibited at a 10 lmol/L concentration of AJA. Treatment of HD-
exposed human epidermal keratinocyte cultures with AJA also
improved morphological changes associated with SM toxicity
observed by phase-contrast microscopy. Chemical warfare dates
back to 1000 BC with the use of arsenical smokes by the Chinese.
Recent events in the Middle East have renewed the need for effec-
tive treatment of injuries resulting from exposure to nerve and blis-
ter agents. The actions of AJA described above suggest its use as
one possibility.
2.6 | Pathogen resolution comparing wild type with
CFTR-deficient mice; a model for CF
Pulmonary infection and inflammation are major factors in the mor-
bidity and mortality in CF. A study was performed to determine the
safety of AJA in a murine model of chronic Pseudomonas aeruginosa
(PA) lung infection and inflammation, and to establish the therapeu-
tic potential of AJA in CF lung infection using chronically infected
CFTR-deficient mice.16 In the first series of studies, wild-type (WT)
C57BL/6J animals were utilized to evaluate oral dosing, safety and
toxicity of AJA. In the second series of studies, a limited number of
both WT and CF mice were evaluated for safety, toxicity, and effi-
cacy upon oral dosing AJA. As controls, PA infected WT and CF
mice were given the vehicle. The mice were followed daily for clini-
cal score and weights for 10 days. At day 10, animals were eutha-
nized and evaluated for bacterial load (colony forming units [CFUs]),
total and differential bronchoalveolar lavage (BAL) white blood cell
counts (WBCs). In the first study in WT mice, AJA was well tolerated
and more efficient at resolving both inflammation and infection than
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F IGURE 2 Ajulemic acid increases survival time in an inverse
dose-response relationship in a mouse glioma model (Recht L and
Salmonsen R, unpublished). High dose, 10 mg/kg; low dose, 0.1 mg/
kg. AJA administration began 1 day after U87MG cell inoculation
into the right flank of SCID-NOD mice. N = 5/group. Calculated
using Prism and the method of Kaplan and Meier. AJA, ajulemic acid
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vehicle. CF mice have a more robust inflammatory response to PA
infection, and, untreated, are very inefficient at resolving the bacte-
rial burden. Postinfection CF mice lose significant weight and have
higher clinical scores. The second study included 4 groups and all
animals were chronically infected with PA. All WT animals survived
PA infection (both vehicle and drug treated); AJA improved survival
of CF mice. Treatment of CF mice with AJA decreased weight loss,
BAL WBC counts, and numbers of neutrophils and improved the
ability of the animals to resolve pulmonary infection as assessed by
lung CFUs. These preliminary data suggest that AJA may be effec-
tive in the treatment of inflammation in CF and improve the sub-
ject’s ability to resolve bacterial infection.
3 | NONCLINICAL DRUG METABOLISM
3.1 | Biotransformations of AJA
The in vitro metabolism of AJA by hepatocytes from rats, dogs,
cynomolgus monkeys, and humans was studied and the results were
reported.18 Five metabolites, M1 to M5, were observed in human
hepatocyte incubations. One metabolite, M5, a glucuronide, was
observed in the chromatogram of canine hepatocyte incubations. In
monkey hepatocyte incubations, M5 was observed in the chro-
matograms of both the 120- and 240-minute samples, a trace
metabolite M1 (side-chain hydroxyl) was observed in the 120-minute
samples, and a trace metabolite M4 (side-chain dehydrogenation)
was observed in the 240-minute samples. No metabolites were
found in the rat hepatocyte incubations. Unchanged amounts of AJA
detected after the 2-hour incubations were 103%, 90%, 86%, and
83% for rat, dog, monkey, and human hepatocytes, respectively.
3.2 | Lack of effects on cytochrome metabolism of
other molecules
Additional studies were done to ascertain if AJA inhibits the activi-
ties of 5 of the principal human cytochrome P450 isozymes; (cy-
tochrome P450 isoform 1A2, cytochrome P450 isoform 2C9,
cytochrome P450 isoform 2C19, cytochrome P450 isoform 2D6,
and cytochrome P450 isoform 3A4/5) CYP1A2, CYP2C9, CYP2C19,
CYP2D6, and CYP3A4/5 involved in drug metabolism. In contrast to
the phytocannabinoids, THC and CBD, that can inhibit these
enzymes, with AJA, no significant inhibition of cytochrome activity
was observed. These data further support the conclusion reached in
earlier reports on AJA’s high margin of safety and indicates that it
undergoes minimal metabolism and is not likely to interfere with the
normal metabolism of drugs or endogenous substances.
4 | CLINICAL TRIALS
4.1 | Pharmacokinetics
As part of a Phase 1 safety trial, the pharmacokinetics of single oral
doses of 0-10 mg of AJA was carried out (Atlantic Pharmaceuticals,
unpublished data). A group of 32 healthy adult male subjects was
monitored by mass spectrometric methods for 24 hours after dosing.
The data showed that AJA was rapidly absorbed and is eliminated
with a half-life of about 3 hours. A linear relationship of the area
under the curve (AUC) and Cmax over the 1-10 mg dose range was
observed.
4.2 | Systemic sclerosis or scleroderma)
Scleroderma, or systemic sclerosis (SSc), is a chronic connective tissue
disease generally classified as one of the autoimmune rheumatic dis-
eases. It is estimated that about 90 000 people in the United States
and Europe have been diagnosed with SSc. Currently, there is no cure
for SSc, but there are several treatments available to relieve specific
symptoms. The changes occurring in SSc may affect the connective
tissue in many parts of the body. It can involve the skin, esophagus,
gastrointestinal tract, lungs, kidneys, heart, and other internal organs.
It can also affect blood vessels, muscles, and joints. The tissues of
involved organs become hard and fibrous, causing them to function
less efficiently. Inflammation is thought to be the driving force behind
the disease, leading to increased fibrosis and ultimate mortality.
Regarding molecular events, the proinflammatory and profibrotic cyto-
kine TGF-b has been identified as an important mediator.
A multicenter, double-blinded, randomized, placebo-controlled
Phase 2 trial to evaluate the safety, tolerability, pharmacokinetics,
and efficacy of AJA in subjects with diffuse cutaneous SSc was
recently completed (ClinicalTrials.gov; reference Identifier
NCT02465437).1,2 Subjects with disease durations of up to 6 years
were randomized to receive AJA for the first 4 weeks at 5 mg once
a day, 20 mg once a day, 20 mg twice a day, or placebo for the first
4 weeks; subsequently, all drug-treated subjects received 20 mg
twice a day for the next 8 weeks while subjects who had received
placebo the first 4 weeks remained on placebo. After 12 weeks, all
drug or placebo treatments were stopped and subjects were fol-
lowed up for another 4 week “washout” period. AJA out-performed
placebo in the American College of Rheumatology Combined
Response Index (CRISS) score in diffuse cutaneous SSc. Higher
CRISS scores mean greater improvement; a CRISS score ≥20%
(CRISS20) is considered a medically meaningful improvement. Differ-
ences in categorical levels of CRISS responses and changes from
baseline in each of the 5 individual domains of the CRISS score also
supported clinical benefit of AJA. The data from this Phase 2 study
show that AJA has the potential to provide clinical benefit in
patients with systemic sclerosis (SSc).
To corroborate the clinical findings in the SSc trial with quantita-
tive biomarkers, skin biopsies from patients enrolled in the clinical
trial were evaluated for changes in gene expression by Whitfield
et al3 There were significant differences seen between samples from
AJA-treated patients when compared with samples from placebo
arms of the study. Extracellular matrix-related genes important for
fibrotic responses and inflammation-related genes were decreased,
whereas lipid metabolism genes important for generating proresolv-
ing eicosanoids were increased. These gene expression changes were
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correlated with AJA-induced changes in the modified Rodnan skin
score, a clinical measure of skin fibrosis.
In April 2016, the sponsor, Corbus Pharmaceuticals, received
FDA approval for an open-label extension to its Phase 2 trial of AJA
for SSc.4 Subjects entering this open-label trial will undergo a 28-day
screening period, then receive 20 mg BID AJA for 364 days, ending
with a 28-day washout after the last dose. This study will provide
important additional data on long-term use of AJA in SSc patients.
Recently, Corbus announced FDA approval to move forward
with a pivotal Phase 3 clinical trial of AJA in SSc and this trial has
now been initiated. This international Phase 3 trial will be a double-
blind, randomized, placebo-controlled study conducted in ~350
adults with SSc. Subjects will be randomized to receive AJA 20 mg
twice per day, AJA 5 mg twice per day, or placebo twice per day.
The primary efficacy outcome of the Phase 3 study will be the
change from baseline at week 52 in modified Rodnan skin scores
(“mRSS”), a measure of skin thickening and a validated clinical out-
come in SSc. Secondary outcomes of the Phase 3 study will include
the American College of Rheumatology Combined Response Index in
Diffuse Cutaneous Systemic Sclerosis (“ACR CRISS”) score, a com-
posite measure of clinical improvement from baseline that incorpo-
rates change from baseline in mRSS lung function, and other
physician and patient reported outcomes.
4.3 | Cystic fibrosis
Cystic fibrosis (CF) is a genetic disorder that affects not only the
lungs, but also the pancreas, liver, kidneys, and intestine. CF is inher-
ited in an autosomal recessive manner. It is caused by the presence
of mutations in both copies of the gene for the CF transmembrane
conductance regulator (CFTR) protein. CFTR is involved in produc-
tion of sweat, digestive fluids, and mucus. When CFTR is not func-
tional, secretions that are usually thin instead become thick. Long-
term issues include difficult breathing and coughing up of mucus as
a result of frequent lung infections. Lung infections are treated with
antibiotics that may be given intravenously, inhaled, or by mouth.
The average life expectancy is between 42 and 50 years in the
developed world. Eighty percent of deaths in CF are due to lung
problems.
Recently a Phase 2, double-blinded, randomized, placebo-con-
trolled multicenter study to evaluate safety, tolerability, and pharma-
cokinetics of AJA in CF was completed (ClinicalTrials.gov Identifier:
NCT02465450) and the topline results have been reported.18,5,6 This
trial tested the safety, tolerability, and pharmacokinetics (PK) of AJA
in 85 subjects between 18 and 65 years of age with documented
CF. An earlier trial in healthy humans measured PK values and is dis-
cussed above. There was a screening period of up to 28 days,
84 days of treatment, and 28 days of follow-up. Primary endpoints
were safety and tolerability while secondary endpoints were trends
in efficacy (FEV1, Lung Clearance Index, and CFQ-R Respiratory
Symptom Score) and PK. Exploratory endpoints were metabolipido-
mic profile for MOA, biomarkers of disease activity and inflammation
in blood and sputum, and microbiota in the lungs.
This Phase 2 clinical trial met all primary endpoints and
showed promising effects in the exploratory endpoints.18 Specifi-
cally, safety and tolerability were acceptable, not a trivial result
considering those have been the main reasons why other anti-
inflammatory drugs (eg, ibuprofen and prednisone) have not been
adopted for use in CF despite evidence of efficacy.19 Because CF
patients have problems absorbing ingested substances, it was
important to evaluate the pharmacokinetics of AJA in CF patients.
Drug exposures were very similar in the CF patients compared to
healthy volunteers indicating that the pharmacokinetics of AJA
was not altered. AJA showed evidence of biological activity in the
lungs with reduction in multiple inflammatory cells and mediators.
Specifically, reductions in neutrophils, eosinophils, lymphocytes,
and macrophages were seen in the sputum from AJA-treated sub-
jects compared to patients receiving placebo, and these effects
were dose-related. Most remarkable, a dose-related reduction in
the rate of pulmonary exacerbations was also noted. Pulmonary
exacerbations are believed to have a major detrimental impact on
lung function in CF patients. Lung function remained stable
throughout the study, and was not expected to improve given the
short duration of the trial.
While the study was not powered to establish efficacy, the
potential for AJA as an effective inflammation-resolving agent that
can broadly target CF patients, without regard to their specific CFTR
gene mutations, was suggested. This is in contrast to other drugs,
such as ivacaftor, that target a specific gene and are therefore only
effective in a subset of CF patients.20
4.4 | Reduction of inflammation in alveolar
macrophages from CF patients
A translational study on the effects of AJA using macrophages
from lungs removed from 2 CF patients undergoing lung trans-
plant was recently carried out by Motwani et al7 https://doi.org/
10.1002/ppul.23837. Cultured macrophages were treated with a
lipopolysaccharide derived from P. aeruginosa, which is a major
bacterial pathogen in CF, to stimulate a cytokine (inflammatory)
response. AJA inhibited LPS-stimulated production of TNF-a and
IL-6 in a dose-dependent fashion. Inflammatory cytokine levels are
generally elevated in lung macrophages from CF subjects.21
Chronic bacterial infection in CF lungs is associated with an
excessive inflammatory response, characterized by elevated cyto-
kine levels.
4.5 | Dermatomyositis
Dermatomyositis (DM) is a connective tissue disease that is charac-
terized by inflammation of the muscles and the skin. It is a systemic
disorder that may also affect the joints, the esophagus, the lungs,
and the heart. In the United States, the incidence of DM is esti-
mated at 5.5 cases per million people.
An in vitro study using peripheral blood mononuclear cells
(PBMCs) from dermatomyositis patients showed that AJA treatment
BURSTEIN | 5 of 10
significantly reduced the production of pathogenic cytokines in a
dose-related manner compared with vehicle controls.22 Specifically,
moderate and high AJA concentrations significantly reduced TNF-a
secretion; all doses significantly decreased the levels of IFN-a. Cell
viability was always greater than 95% following treatment with AJA
or vehicle control. These encouraging data supported the initiation
of a phase 2 clinical trial.
An NIH supported phase 2 trial of AJA entitled “double-blind,
randomized, placebo-controlled study to investigate the safety, toler-
ability, and efficacy in subjects with dermatomyositis” is currently
ongoing8 (ClinicalTrials.gov Identifier: NCT02466243). The primary
outcome measures are: (1) number of participants with treatment
emergent adverse events as a measure of safety and tolerability, and
(2) change in the cutaneous dermatomyositis disease area and sever-
ity index from baseline at 84 days.
The secondary outcome measures are: (1) change in patient-
reported outcomes from baseline at 84 days; (2) change in blood
biomarkers of inflammation and disease activity from baseline at
84 days; (3) change in skin biomarkers of inflammation from baseline
at 84 days; (4) change in plasma metabolipidomic profiles from base-
line at 84 days; and (5) change in AJA plasma concentrations from
baseline through 84 days.
The FDA has approved a 1-year, open-label extension study of
the ongoing phase 2 clinical trial of AJA for the treatment of skin-
predominant dermatomyositis. The goal of the open-label study is to
collect long-term safety and efficacy data on AJA. The safety and
efficacy endpoints used in the double-blinded, placebo-controlled
portion of the study will be measured throughout the 1-year exten-
sion study.
5 | SAFETY AND TOLERABILITY
5.1 | Lack of ulcerogenicity
The most significant unwanted side effect of many anti-inflammatory
agents is the formation of gastrointestinal ulcers. For this reason, AJA
was carefully examined to detect any possible ulcerogenicity. When
given acutely to rats in doses up to 1000 mg/kg, no evidence for ulcer
formation was seen. Chronic intragastric administration of up to
30 mg/kg likewise resulted in no ulcerogenicity, whereas the positive
control indomethacin-treated rats showed extensive ulcer forma-
tion.23 AJA has a very favorable therapeutic index for ulcerogenicity
vs inflammation when compared to several NSAIDs (Table 1).
5.2 | Toxicity
Because of its structural similarity to THC, AJA was studied for pos-
sible induction of opiate like physical dependence in a 14-day rat
study.24 None of the typical opiate withdrawal effects such as wri-
thing, diarrhea, wet dog shakes, etc., were observed indicating that
AJA has a low dependence liability. There were no effects on renal,
cardiovascular, or gastrointestinal function, and no signs of respira-
tory depression as well. Lethal doses were estimated following single
doses in mice (600 mg/kg) and in rats (400 mg/kg). AJA was well
tolerated at doses up to 50 mg/kg. Three different standard tests
for mutagenic potential gave negative findings.
6 | MECHANISM OF ACTION
6.1 | Cannabinoid receptors
In recent years, the discovery of CB2-specific agonists has been an
important goal in the area of therapeutics. CB2 is a member of the
G-protein-coupled receptor (GPCR) superfamily and its pharmacology
has been reviewed in some detail.25 CB2 receptors are primarily
expressed in the periphery, including cells involved in immune sys-
tem activities. Although CB2 has been detected in the CNS, its
actions do not include mood alteration or behavioral responses.
Receptor binding studies using highly purified preparations of AJA
showed ~12-fold selectivity for CB2 over CB1 receptors, whereas
preparations described in previous reports showed much higher
activity at CB1 relative to CB2 (Table 2). The highly purified prepara-
tion of AJA stimulated release of PGJ in a CB2-dependent manner
and produced minimal catalepsy or hypothermia, effects primarily
mediated by CB1 receptors.2 In contrast, AJA preparations described
in earlier reports had higher CB1 binding activity and caused con-
comitantly greater catalepsy and hypothermia,2 suggesting possible
contamination by impurities such as 11-hydroxy-DMH-THC, an
intermediate in the synthesis of AJA.
6.2 | Drug distribution
The structure of AJA suggests an inability to cross the blood-brain
barrier in humans due to its polarity and molecular weight. Evidence
from distribution studies in rats is in agreement with this possibil-
ity.26 Therefore, in addition to its selectivity for CB2 over CB1, the
poor brain uptake of AJA will further favor its actions toward acti-
vating CB2 receptors on immune cells in the periphery, as opposed
to stimulating CB1 receptors in the CNS.
TABLE 1 Therapeutic index of AJA compared with selected
NSAIDsa
Drug Therapeutic index
Ajulemic acid >300
Ketorolac 7.28
Ketoprofen 41.0
Indomethacin 13.3
Diclofenac 13.8
Ibuprofen 3.59
AJA, ajulemic acid; NSAID, nonsteroidal anti-inflammatory drug.
aThe therapeutic indices were calculated from the ratio of the ED50
ulcerogenicity/ED-50 adjuvant-induced arthritis in the rat (95% confi-
dence limits). The ED50 values for AJA are estimates since a dose of up
to 30 mg/kg/day did not produce detectable ulceration (E. Dajani,
unpublished data). The ED50 in the rat adjuvant arthritis test for AJA is
estimated.3
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6.3 | Preclinical mechanism studies
The major precursor for all of the eicosanoids is free arachidonic acid
(AA) whose release from phospholipid storage sites is robustly stimu-
lated by AJA (Figure 3).27 This initiates a cascade of events leading
to the eicosanoid superfamily, one branch of which is shown in Fig-
ure 4. Several members of the eicosanoid superfamily shown in Fig-
ure 4 have been implicated in the events that regulate the
resolution of chronic inflammation.28 A group of these known as the
cyclopentenone prostaglandins are the result of nonenzymically
mediated conversions of prostaglandin D2 (PGD2), which is a beta-
hydroxy ketone to the PGJ series. As could be expected, the resul-
tant alpha, beta-unsaturated ketone is subject to possible Michael
addition reactions with various molecules that may be available. The
terminal product of PGD2 metabolism is 15-deoxy-D
12,14-prostaglan-
din-J2 (PGJ). PGJ has been shown to suppress various proinflamma-
tory signaling pathways such as those that function through NF-kB,
AP1, signal transducers and activators of transcription. PGJ also
causes suppression of inducible nitric oxide synthase, interleukin-1a,
TNF-b, and IL-12.
Regulation of eicosanoids involved in resolution of inflammation
by AJA may occur through CB2 and at several other places within
the cascade shown in Figure 4. The bifunctional enzyme COX-2 oxi-
dizes AA to PGG2 and a subsequent peroxidase reaction leads to
PGH2. Then, mediated by the terminal PGD synthase, PGD2 is
formed, which in turn is transformed to the PGJ series in an unregu-
lated manner. In addition to stimulating production of AA, AJA stim-
ulates COX-2 activity, and has a selective effect on PGD synthase
activity. All of this results in an increase in levels of the proresolving
PGJ, however, there is little change in the level of the proinflamma-
tory prostaglandin PGE2 (data not shown).
The ability of AJA to increase the production of the proresolving
eicosanoid PGJ has been confirmed experimentally; application of
AJA to HL60 cells produced a robust stimulation of PGJ.27 The AJA-
induced increase in PGJ was effectively inhibited by the CB2
TABLE 2 Cannabinoid receptor binding data for several ajulemic acid preparationsa
Ligand Ki CB1 Ki CB2 CB1/CB2 Reference
Ultrapure AJA (JBT-101) 628 51 12.3 Tepper et al32
Ajulemic acid 5.7 56.1 0.10 Dyson et al26
Ajulemic acid 32.3 170.5 0.19 Rhee et al33
WIN-55,212b 1.89-123 0.28-16.2 ND Pertwee et al34
SR144528b 50.3-10 000 0.28-5.6 ND Pertwee et al34
SR141716b 1.8-12.3 514-13 200 ND Pertwee et al34
AJA, ajulemic acid.
aAll Ki values are expressed in nmol/L units of concentration.
bIncluded for comparison with AJA. SR144528 is a widely used CB2 antagonist. SR141716 is a CB1 antagonist also called Rimonabant.
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F IGURE 3 AJA induces release of free arachidonic acid in C6
glioma cells (Burstein SH, unpublished data). Cells were labeled for
20 hour with 14C-arachidonic acid, media (RPMI + 0.1% BSA) were
changed and cells were treated for indicated times with AJA in
10 lL of DMSO. The control was 10 lL of DMSO. Release was
measured by liquid scintillation counting on a 0.1 mL aliquot of
medium. Values shown are means  SD. N = 4. AJA, ajulemic acid
Phospholipids
Arachidonic
      acid
COX-2
PGG2
COX-2
5- and 15-lipoxygenases
Lipoxin A4
    PGH2
PGD synthase
PGD215d-PGJ2
Resolution of
inflammation
Unregulated
CB2
F IGURE 4 In vitro CB2-initiated pathways for the synthesis of
the proresolving eicosanoids PGJ2 and LXA4. All of the steps are
tightly regulated except for the conversion of PGD2 to PGJ2, which
proceeds in the absence of enzymic mediation. PGD2, prostaglandin
D2; LXA4, lipoxin A4
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antagonist SR144528 (1 lmol/L), whereas the CB1 antagonist
SR141716 (10 lmol/L) had only a small effect, suggesting a CB2
receptor-mediated mechanism of action.1,27
A second eicosanoid, lipoxin A4 (LXA4), has also been reported
to contribute to the inflammation resolving action of AJA.29 In a dif-
ferent branch of the arachidonic acid cascade, LXA4 production
results from the sequential actions of 5- and 15-lipoxygenases
(LOX) following the release of free arachidonic acid (Figure 4).29 It
was further shown that the 12/15 LOX inhibitor baicalein reduces
this action of AJA. LXA4 is an important member of the emerging
class of molecules known as specialized proresolving mediators
(SPMs) that promote the resolution of chronic inflammation.30 Fol-
lowing trauma or tissue injury, SPMs play pivotal roles in vascular
responses and leukocyte trafficking, from initiation to resolution.
Organ fibrosis can be an ultimate result of unresolved chronic
inflammation.
6.4 | Mechanism studies in humans
To further explore its mechanism of action, and establish a pharma-
codynamic relationship between dose and effect, ultrapure AJA, was
evaluated in a model of experimental inflammation in humans. This
model utilizes intradermal injection of UV-killed Escherichia coli into
the forearm of healthy volunteers.31 Inflammation was detected by
increased blood flow, neutrophilia, and increased levels of proinflam-
matory cytokines. Resolution was observed by a decrease in blood
flow, a reduction in neutrophils, an increase in monocytes/macro-
phages, and a drop of classic proinflammatory cytokine levels. It was
claimed that this model can provide mechanistic insights and can
help evaluate the clinical potential of novel anti-inflammatory and
proresolving drugs.
AJA was studied in the above model and preliminary data were
reported by Gilroy et al9 Subjects were divided into 3 groups of 5,
each receiving 5 mg or 20 mg BID AJA, or placebo, all of which
were given before the procedure. Both doses of AJA caused a 70%
reduction in inflammation based on a decrease in neutrophil infiltra-
tion and decreased blood flow around the site of inflammation. In
addition, the treatment resulted in a progressive increase in blood
flow around the site of inflammation during the early phases of reso-
lution indicative of an efficient inflammatory response followed by a
timely resolution9.
7 | SUMMARY AND CONCLUSIONS
Thus far, the available preclinical (Table 3) and clinical data (Table 4)
suggest that AJA could provide a safe and effective treatment for
diseases that are characterized by chronic inflammation and eventu-
ally result in fibrosis, loss of function, etc. Data from in vitro experi-
ments suggest that the CB2 receptor is an important mediator and
that AJA can act as an inflammation-resolving agent through its
stimulatory action on the production of the proresolving agents PGJ
and LXA4. Its ability to lower IL-1b inhibitor a factor in some of its
actions. Based on its structural overlap with AA, it has been sug-
gested that AJA should be referred to as an arachidomimetic agent.1
Therapeutic targets for AJA such as scleroderma, CF, dermatomyosi-
tis, lupus, arthritis, MS, and metastatic cancer are possibilities based
on the current body of data. Its lack of adverse side effects makes it
especially suitable for chronic administration. Finally, a long-standing
goal in the cannabinoid field has been the separation of therapeutic
actions of THC from its psychoactivity. AJA appears to represent, in
a large measure, such an achievement of this goal.
TABLE 3 Reported preclinical anti-inflammatory and antifibrotic actions of ajulemic acid
Observed action Model Reference
Reduces paw edema in mice Arachidonate or PAF induction Burstein et al35
Reduces leukocyte adhesion Mouse peritoneal cells Burstein et al35
Decreases joint damage Adjuvant-induced arthritis in rats Zurier et al3
Reduces leukocyte migration Subcutaneous air pouch Zurier et al3
Reduces MS-induced spasticity EAE mouse model Pryce et al6
Antimetastatic Effects Mouse glioma in vivo Recht L et al, unpublished.
Reduction of IL-1b levels Blood and synovial monocytes Zurier et al12
Inhibits matrix metalloproteinases Human synovial cells Johnson et al14
Inhibits cell proliferation in vitro Several cancer cell lines Recht et al9
Apoptosis of human T cells Caspase-3 activity Bidinger et al4
Potent antifibrotic actiona Bleomycin in mice Gonzalez et al7, Lucattelli et al8
Pathogen resolutiona CFTR-deficient mice Bonfield et al16
Reduced peritoneal cell infiltration Zymosan-induced peritonitis Zurier et al29
Antichemical blister activity Human keratinocyte cell cultures Atlantic Pharmaceuticals, unpublished
AJA, ajulemic acid; CFTR, CF transmembrane conductance regulator.
aThe ultrapure preparation of AJA (JBT-101) with reduced CB1 activity was used for these studies.32
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